Analysis of Сandida species distribution isolated from women with vulvovaginal candidiasis and their antifungal susceptibility profile
Keywords:Candida non-albicans, Candida albicans, VVC, antifungal agents
Background. Candida species is usually a commensal fungus residing in the vagina, in about 30 %–50 % of healthy adults and remains the most common agent isolated from clinical samples of patients diagnosed with vulvovaginal candidiasis (VVC). Culture is not recommended for all patients on a routine basis but is informative for the exclusion of non-albicans infections resistant to azoles, or recurrent VVC. Identification of Candida species and antifungal susceptibility testing are key elements in the correct management of recurrent VVC. The authors of this paper aimed to study the spectrum of pathogenic Candida species. The antifungal sensitivity patterns of the isolated strains during the years 2017-2019 are also presented. Material and methods. A descriptive study of Candida species distribution and antifungal susceptibility profile was performed. Identification of isolated Candida species was performed by the MALDI-TOF MS, bacterial strains by Vitek 2 automated system (BioMérieux) and antifungal susceptibility profiles by Fungitest (Bio-Rad). Results. Of the 1030 recovered strains, C. albicans species predominated - 83.8% and Candida non albicans -16.2%. The most common species of the Candida non-albicans, were C.glabrata (7.5%). Also, it was observed that in 56.6% of the cases C. albicans presented bacterial associations. The most common microbial association was C. albicans and S.aureus (26.6%), followed by C. albicans and E.coli (20.8%). Candida spp. showed moderate antifungal resistance. The resistance rate of C. albicans isolates to miconazole, fluconazole and itraconazole was 25.5%, 17.0% and 11.4% compared to non-albicans Candida strains which showed a resistance rate of 10,8%, 14.4% and 10%, respectively. Conclusions. C. albicans is the most frequently isolated species among patients with VVC, but there is also an increase share of non-albicans Candida species such as C. glabrata. C. albicans isolates showed higher indices of resistance, than Candida non-albicans.
Höfs S, Mogavero S, Hube B. Interaction of Candida albicans with host cells: virulence factors, host defense, escape strategies, and the microbiota. J Microbiol. 2016; 54: 149-169.
Fidel PL. History and new insights into host defense against vaginal candidiasis. Trends Microbiol. 2004 May;12(5):220-7. doi: 10.1016/j.tim.2004.03.006. PMID: 15120141.
Aballéa S, Guelfucci F, Wagner J et al. Subjective health status and health-related quality of life among women with recurrent vulvovaginal candidosis (RVVC) in Europe and the USA. Health Qual Life Outcomes. 2013; 11: 169.
Foxman B, Barlow R, D'Arcy H, Gillespie B, Sobel JD. Candida vaginitis: self-reported incidence and associated costs. Sex Transm Dis. 2000; 27: 230- 235.
Sobel JD. Vulvovaginal candidosis. Lancet. 2007; 369: 1961- 1971.
Jacob L, John M, Kalder M, Kostev K. Prevalence of vulvovaginal candidiasis in gynecological practices in Germany: a retrospective study of 954,186 patients. Curr Med Mycol. 2018; 4: 6- 11.
Geiger AM, Foxman B, Gillespie BW. The epidemiology of vulvovaginal candidiasis among university students. American Journal of Public Health. 1995;85(8):1146–1148.
Chowdhary A, Meis J. Antifungal resistance in clinically significant fungi. Fungal Genetics and Biology 139:103369 DOI: 10.1016/j.fgb.2020.103369.
Fidel PL, Cutright J, Steele C. Effects of reproductive hormones on experimental vaginal candidiasis. Infect Immun 2000;68:651-7.
Gonçalves B, Ferreira C, Alves CT, Henriques M, Azeredo J, Silva S. Vulvovaginal candidiasis: Epidemiology, microbiology and risk factors. Crit Rev Microbiol. 2016;42(6):905-927. doi:10.3109/1040841X.2015.1091805.
Richter SS, Galask RP, Messer SA, Hollis RJ, Diekema DJ, Pfaller MA. Antifungal susceptibilities of Candida species causing vulvovaginitis and epidemiology of recurrent cases. J Clin Microbiol. 2005; 43: 2155- 2162.
Grigoriou O, Baka S, Makrakis E, Hassiakos D, Kapparos G, Kouskouni E. Prevalence of clinical vaginal candidiasis in a university hospital and possible risk factors. Eur J Obstet Gynecol Reprod Biol. 2006; 126: 121- 125.
Makanjuola O, Bongomin F, Fayemiwo SA. An Update on the Roles of Non-albicans Candida Species in Vulvovaginitis. J Fungi (Basel). 2018 Oct 31;4(4):121. doi: 10.3390/jof4040121. PMID: 30384449; PMCID: PMC6309050.
Ferris DG, Nyirjesy P, Sobel JD, Soper D, Pavletic A, Litaker MS. Over-the-counter antifungal drug misuse associated with patient-diagnosed vulvovaginal candidiasis. Obstet Gynecol. 2002; 99: 419- 425.
Mendling W, Brasch J. German Society for Gynecology and Obstetrics. Guideline vulvovaginal candidosis (2010) of the German Society for Gynecology and Obstetrics, the Working Group for Infections and Infectimmunology in Gynecology and Obstetrics, the German Society of Dermatology, the Board of German Dermatologists and the German Speaking Mycological Society. Mycoses. 2012;55:Suppl 3:1. doi: 10.1111/j.1439-0507.2012.02185.
Rathod SD, Klausner JD, Krupp K, Reingold AL, Madhivanan P. Epidemiologic features of Vulvovaginal Candidiasis among reproductive-age women in India. Infect Dis Obstet Gynecol. 2012;2012:859071. doi:10.1155/2012/859071.
Colombo AL, Guimarães T, Aranha LF. Brazilian guidelines for the management of candidiasis - a joint meeting report of three medical societies: Sociedade Brasileira de Infectologia, Sociedade Paulista de Infectologia and Sociedade Brasileira de Medicina Tropical. Braz J Infect Dis vol.17 no.3 Salvador May/June 2013. http://dx.doi.org/10.1016/j.bjid.2013.02.001.
Diba K, Namaki A, Ayatolahi H, Hanifian H. Rapid identification of drug resistant Candida species causing recurrent vulvovaginal candidiasis. Med Mycol J. 2012;53:193.
Weissenbacher T, Witkin SS, Ledger WJ. Relationship between clinical diagnosis of recurrent vulvovaginal candidiasis and detection of Candida species by culture and polymerase chain reaction. Arch Gynecol Obstet. 2009;279:125. doi: 10.1007/s00404-008-0681-9.
Доброхотова ЮЭ, Боровкова ЕИ, Бондаренко КР. Кандидозный вульвоваги-нит: состояние изученности проблемы. Российский вестник акушера-гинеколога. 2017;17(3):108-111.
Anderson MR, Klink K, Cohrssen A. Evaluation of vaginal complaints. JAMA. 2004; 291:1368–1379. doi: 10.1001/jama.291.11.1368.
Ahmad A, Khan AU. Prevalence of Candida species and potential risk factors for vulvovaginal candidiasis in Aligarh, India. Eur J Obstet Gynecol Reprod Biol. 2009;144:68–71. doi: 10.1016/j.ejogrb.2008.12.020.
Olowe OA, Makanjuola OB, Olowe R, Adekanle DA. Prevalence of vulvovaginal candidiasis, trichomoniasis and bacterial vaginosis among pregnant women receiving antenatal care in Southwestern Nigeria. Eur J Microbiol Immunol. 2014;4:193–197. doi: 10.1556/EUJMI-D-14-00027.
Sobel JD. Candida vulvovaginaitis. Clin Obstet Gynecol. 1993.36:153-65. 9.
Sobel JD, Chaim W. 1997. Treatment of Torulopsis glabrata vaginitis: A retrospective review of boric acid therapy. Clin Infect Dis 24:649-52. 10.
Spinillo A, Capuzzo E, Gulminetti R et al. Prevalence of and risk factors for fungal vaginitis caused by non-albicans species. Am J Obstet Gynecol. 1997.176:138-41.
Singh S, Sobel JD, Bhargava P, Boikov D, Vazquez JA. Vaginitis due to Candida krusei: Epidemiology, clinical aspects, and therapy. Clin. Infect. Dis. 2002;35:1066–1070. doi: 10.1086/343826.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our edition uses the copyright terms of Creative Commons for open access journals.
Authors, who are published in this journal, agree with the following terms:
- The authors retain rights for authorship of their article and grant to the edition the right of first publication of the article on a Creative Commons Attribution 4.0 International License, which allows others to freely distribute the published article, with the obligatory reference to the authors of original works and original publication in this journal.
- Directing the article for the publication to the editorial board (publisher), the author agrees with transmitting of rights for the protection and using the article, including parts of the article, which are protected by the copyrights, such as the author’s photo, pictures, charts, tables, etc., including the reproduction in the media and the Internet; for distributing; for the translation of the manuscript in all languages; for export and import of the publications copies of the writers’ article to spread, bringing to the general information.
- The rights mentioned above authors transfer to the edition (publisher) for the unlimited period of validity and on the territory of all countries of the world.
- The authors guarantee that they have exclusive rights for using of the article, which they have sent to the edition (publisher). The edition (the publisher) is not responsible for the violation of given guarantees by the authors to the third parties.
- The authors have the right to conclude separate supplement agreements that relate to non-exclusive distribution of their article in the form in which it had been published in the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
- The policy of the journal permits and encourages the publication of the article in the Internet (in institutional repository or on a personal website) by the authors, because it contributes to productive scientific discussion and a positive effect on efficiency and dynamics of the citation of the article.
- The rights to the article are deemed transferred by the authors to the edition (the publisher) since the moment of the publication of the article in the printed or electronic version of journal.